ADMA at a glance
ADMA BIOLOGICS, INC. (ADMA, SEC CIK 1368514) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as July 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ADMA BIOLOGICS, INC. (ADMA) reported revenue of $510.2 million (up 19.6% from FY2024) and net income of $146.9 million. Diluted EPS was $0.60.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding ADMA BIOLOGICS, INC. (ADMA) shares worth $913.0 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Grossman Jerrold B on May 27, 2026 of 6,400 shares at $7.91 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $510.2M
- +19.6% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 32 funds
- $913.0M · −1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: End-to-end biopharmaceutical company manufacturing specialty biologics for immunodeficient and immune-compromised patients
- New emphasis on SG-001 for prevention/treatment of S. pneumoniae infections, with pilot batch completed and pre-IND planned in FY 2026
- Strategic shift: Divestiture of 3 plasma centers, moving to more flexible, capital-efficient plasma supply; 7 centers to remain operational post-divestiture
- Quantitative highlight: 20%+ production yield increase from FDA-approved yield enhancement process effective April 2025, first full year in FY 2026
- Noteworthy: Implementation of AI platform ADMAlytics started in 2024 to optimize plasma pooling and commercial operations, with ongoing expansion in 2025
Risk Factors
- FDA inspections risk: potential issuance of warning letters or enforcement actions due to non-compliance with cGMP at ADMA or third-party contractors
- Geopolitical exposure: supply chain disruptions and sales impact from Russia-Ukraine conflict and sanctions, plus risks in South America, Northern Africa, Middle East
- Supply chain vulnerability: reliance on third-party fill/finish contractors and plasma suppliers may delay finished drug product availability and commercialization
- Competitive risk: uncertain market acceptance and forecast inaccuracies for ASCENIV and plasma-derived products despite FDA approval and new manufacturing yield enhancements
- Financial risk: dependency on key customers accounting for significant revenue and risk of financial strain from need for additional equity/debt if profitability not maintained
Management Discussion & Analysis
- Revenue $510.2M in 2025, up 20% YoY from $426.5M, driven by ASCENIV ($362.5M, +51%), offset by BIVIGAM decline (-14%)
- Gross margin improved to 57.4% in 2025 vs 51.5% in 2024, due to favorable IG product mix and lower manufacturing costs
- Best segment ADMA BioManufacturing: $493.1M revenue (+19%), worst Plasma Collection Centers: $17.0M (+62%), but much smaller base
- Operating cash flow positive $118.7M in 2024, continued positive in 2025; $12.6M real estate acquisition; divestiture of 3 plasma centers for $12.0M in Dec 2025
- 2026 outlook: full year benefit of 20%+ yield enhancement process expected to drive margin expansion; FDA label expansion for ASCENIV anticipated H1 2026
AI summary of the ADMA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $124.4M, up 2.0% YoY from $122.0M
- Gross margin 69.4% vs 55.1% YoY
- ASCENIV revenue $102.9M, up 23.5%; BIVIGAM $19.4M, down 48.5%
- Net income $37.8M vs $34.2M YoY
- Competitive pricing pressure across IVIG markets, particularly BIVIGAM, affecting first-half 2026 results
Risk Factors
- Newly added AI risk, triggered by development and use of artificial intelligence, creating potential reputational harm and increased liability exposure
- Securities litigation risk, with ADMA and directors and officers named as defendants in a class action lawsuit
- FDA compliance risk, where inspections may produce Form 483 observations, warning letters, recalls, or supply disruptions
- Supply-chain risk, with third-party fill-finishers and plasma suppliers potentially delaying finished-product availability
- Customer concentration risk, as a few customers historically represented significant revenue and accounts receivable exposure
AI summary of the ADMA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Filing contains no earnings figures or operational metrics for fiscal year 2026
- Report signed August 5, 2026 by Adam S. Grossman, President and Chief Executive Officer
Item EX-99.1: Item EX-99.1
- 2Q revenue $124.4M, up 2%; ASCENIV $102.9M, up 24%, offsetting BIVIGAM revenue decline to $19.4M
- Gross margin expanded to 69% from 55%, driven by ASCENIV mix and yield-enhanced manufacturing
Item 5.07: Submission of Matters to a Vote of Security Holders
- Two Class I directors elected through 2029: Alison C. Finger and Eduardo Rene Salas
- 199,267,547 shares represented, establishing quorum against 232,324,283 shares outstanding
Item 2.02: Results of Operations and Financial Condition
- Filing section contains only signature information dated May 6, 2026
- No earnings figures or operating results included in the provided Item 2.02 text
AI summaries of ADMA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ADMA
Don't miss the next ADMA filing
- Alerts as it files. A push when ADMA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ADMA, by share count.
- Ask anything. An AI agent that reads every ADMA filing and answers with sources.
ADMA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kestenberg-Messina Kaitlin M. | F | Jul 24, 2026 | 3,177 | $8.37 |
| Kohler Terry | A | Jul 16, 2026 | 136,363 | - |
| Kohler Terry | A | Jul 16, 2026 | 85,130 | - |
| Grossman Jerrold B | Buy | May 27, 2026 | 6,400 | $7.91 |
| Grossman Jerrold B | Buy | May 11, 2026 | 12,500 | $8.01 |
| Kestenberg-Messina Kaitlin M. | F | Apr 1, 2026 | 20,362 | $9.11 |
| Guiheen Lawrence P. | G | Mar 17, 2026 | 30,000 | - |
| Guiheen Lawrence P. | G | Mar 17, 2026 | 30,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $258.2M | $426.5M | $510.2M |
| Gross Profit | - | $219.6M | $292.8M |
| Operating Income | - | $139.0M | $191.4M |
| Net Income | - | $197.7M | $146.9M |
| Gross Margin | - | 51.5% | 57.4% |
| Op. Margin | - | 32.6% | 37.5% |
| Net Margin | - | 46.4% | 28.8% |
| Balance Sheet | |||
| Total Assets | - | $488.7M | $624.2M |
| Equity | - | $349.0M | $477.3M |
| ROE | - | 56.6% | 30.8% |
| Per Share | |||
| EPS | - | $0.81 | $0.60 |
| Cash Flow | |||
| Operating CF | - | $118.7M | $50.4M |
| CapEx | $4.8M | $8.2M | $22.6M |
Source: XBRL data in ADMA BIOLOGICS, INC. (ADMA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ADMA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $913.0M |
| Q1 2026 | 33 | $1.03B |
| Q4 2025 | 30 | $1.98B |
| Q3 2025 | 30 | $1.76B |
| Q2 2025 | 29 | $2.14B |
| Q1 2025 | 27 | $1.55B |
| Q4 2024 | 23 | $1.24B |
| Q3 2024 | 19 | $1.02B |
- D.E. Shaw & Co+4.71M (+841%)
- State Street Corp+3.03M (+22%)
- BlackRock+1.52M (+4%)
- Vanguard Portfolio Management LLC+1.22M (+14%)
- AQR Capital Management+1.01M (+196%)
- Citadel Advisors LLC−4.44M (-76%)
- Invesco Ltd−3.58M (-87%)
- Bank of America Corp−2.35M (-59%)
- Millennium Management−2.28M (-66%)
- Franklin Resources−2.14M (-91%)
- Allstate+76.9K
- Blackstone Group−25.6K
- Truist Financial−14.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 223 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ADMA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 3, 2026 | - | - | - |
| 8-K | Mar 27, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
| 4 | Mar 2, 2026 | - | - | - |
| 8-K | Feb 25, 2026 | - | Analysis | - |
| 10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
| 4 | Feb 17, 2026 | - | - | |
| 4 | Feb 11, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ACLX · Arcellx, Inc.Biological Products, (No Diagnostic Substances)
ADMA SEC filings: frequently asked questions
Which institutions hold ADMA stock?
As of June 30, 2026, the largest ADMA BIOLOGICS, INC. (ADMA) holders among the 13F filers tracked by SignalX were BlackRock ($321.0 million), State Street Corp ($143.3 million), Vanguard Capital Management LLC ($84.6 million), Vanguard Portfolio Management LLC ($84.4 million), D.E. Shaw & Co ($44.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ADMA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ADMA BIOLOGICS, INC. (ADMA) reported revenue of $510.2 million (up 19.6% from FY2024) and net income of $146.9 million. Diluted EPS was $0.60. The figures come from the XBRL data in the 10-K.
What are the main risks in ADMA's latest 10-K?
In the 10-K filed February 25, 2026, ADMA BIOLOGICS, INC. (ADMA) flagged: FDA inspections risk: potential issuance of warning letters or enforcement actions due to non-compliance with cGMP at ADMA or third-party contractors. Geopolitical exposure: supply chain disruptions and sales impact from Russia-Ukraine conflict and sanctions, plus risks in South America, Northern Africa, Middle East. (AI summary of the Risk Factors section.)
What did ADMA report in its latest 8-K?
ADMA BIOLOGICS, INC. (ADMA) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Filing contains no earnings figures or operational metrics for fiscal year 2026.
What are the latest ADMA SEC filings?
ADMA BIOLOGICS, INC. (ADMA) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on July 28, 2026.
What is ADMA's SEC CIK number?
ADMA BIOLOGICS, INC. (ADMA)'s SEC Central Index Key (CIK) is 1368514. EDGAR lists every ADMA filing under that number.
Ask anything about ADMA
The research agent reads ADMA's filings, financials, insider trades and 13F holders, then answers with sources.